$0.109
-0.007 (-6.75%)Zum Schluss
BDMD-News
BDMD-Events
Baird Medical Monitors Ordinary Share Price Volatility
Baird Medical has provided the following statement regarding recent volatility in the market price of its ordinary shares: "The Company is closely monitoring these fluctuations in the market price of its ordinary shares and the associated trading activity, and is not currently aware of any material development or otherwise undisclosed reason that would explain the recent decline in its ordinary share price. Baird Medical management believes that the Company's current market valuation does not accurately reflect the strength of its underlying business fundamentals, capabilities, and growth potential. The Company remains committed to the execution of its growth strategy, and to preserving shareholder value."
Baird Medical Enters Exclusive Distribution Agreement with China Resources Medical Devices
Baird Medical announced that its subsidiary in the People's Republic of China, Nanjing Changcheng Medical Equipment Company Limited, has entered into a distribution agreement with China Resources Pharmaceutical Commercial Group Medical Devices, a subsidiary of China Resources Pharmaceutical Group. Under the agreement, China Resources Medical Devices will serve as the exclusive distributor for Baird's specified microwave ablation products in 19 key markets in the People's Republic of China, with a focus on regions where Baird has historically had a limited direct commercial presence. On execution of the agreement, China Resources Medical Devices placed an initial order totaling about RMB 6M, or $900,000. "This partnership with China Resources Medical Devices, one of the leading medical technology distributors in the PRC, provides another important validation of our technology. It will further strengthen our leadership position in China and help accelerate access to hospitals in previously untapped regions. With their extensive distribution network and nationwide prominence, we believe that adding our products to China Resources' portfolio could help drive further adoption of our MWA technology throughout the country. We remain committed to growing our business in the Chinese market, and expect that this agreement will play an important role in achieving this goal while we continue to expand in other key global markets, including the U.S.," said Haimei Wu, chairwoman and CEO of Baird Medical.
Baird Medical Announces Additional Medical Device Registrations in Vietnam
Baird Medical Investment Holdings announced additional medical device registrations in Vietnam. Baird Medical received Class C medical device registration certificates for several products within its microwave ablation portfolio, including its J-series microwave ablation needles for benign thyroid nodules, G-series needles for liver tumors, and MTI-5AT and MTI-5ET microwave ablation generators.
Baird Medical Receives Product Registrations in Pakistan
Baird Medical announced that the BD-GT Microwave Ablation System and T-1610 Disposable Microwave Ablation Needle have received product registrations from the Drug Regulatory Authority of Pakistan, further supporting the company's commercial activities in the country. The registrations build on Baird Medical's existing presence in Pakistan, where the company announced regulatory approvals and initial commercial availability at the Armed Forces Institute of Radiology & Imaging in January. Microwave ablation is increasingly being utilized as a minimally invasive treatment approach for benign and malignant soft tissue tumors, offering physicians the ability to precisely ablate targeted tissue while potentially reducing the burden associated with more invasive surgical procedures. Earlier this year, physicians in Vietnam and Argentina successfully completed their first microwave ablation procedures using Baird Medical's technology, demonstrating the progression from market entry to clinical utilization.
Baird Medical and Tianjin Yuanshan Medical Sign Strategic Cooperation Agreement
Baird Medical and Tianjin Yuanshan Medical announced the signing of a strategic cooperation agreement to establish a long-term partnership focused on global development and commercialization of next-generation IRE technologies. Under the partnership, the companies will initially collaborate on IRE, an advanced, non-thermal ablation technology that uses electrical pulses to destroy targeted tissue while preserving surrounding critical structures, such as blood vessels and nerves. Baird Medical and Alpmed plan to submit a 510 application for the first co-developed product to the FDA by the end of 2026, with the potential to receive regulatory clearance in 2027. The first device is intended for the ablation of soft tissue solid tumors in the liver, breast, thyroid, and prostate. Baird Medical will lead the global regulatory approval processes, including in the U.S., and holds worldwide commercialization rights for this IRE product.
Ähnliche Artikel
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.